Edwards Lifesciences Corporation

Symbol: EW

NYSE

87.42

USD

Market price today

  • 37.1989

    P/E Ratio

  • 2.3869

    PEG Ratio

  • 52.68B

    MRK Cap

  • 0.00%

    DIV Yield

Edwards Lifesciences Corporation (EW) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.77%

Operating Profit Margin

0.26%

Net Profit Margin

0.23%

Return on Assets

0.15%

Return on Equity

0.21%

Return on Capital Employed

0.18%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Devices
CEO:Mr. Bernard J. Zovighian
Full-time employees:19800
City:Irvine
Address:One Edwards Way
IPO:2000-03-27
CIK:0001099800

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.766% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.258%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.230%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.145% return, is a testament to Edwards Lifesciences Corporation's adeptness in optimizing resource deployment. Edwards Lifesciences Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.211%. Furthermore, the proficiency of Edwards Lifesciences Corporation in capital utilization is underscored by a remarkable 0.184% return on capital employed.

Stock Prices

Edwards Lifesciences Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $85.73, while its low point bottomed out at $83.5. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Edwards Lifesciences Corporation's stock market.

Liquidity Ratios

Analyzing EW liquidity ratios reveals its financial health of the firm. The current ratio of 375.45% gauges short-term asset coverage for liabilities. The quick ratio (231.77%) assesses immediate liquidity, while the cash ratio (110.24%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio375.45%
Quick Ratio231.77%
Cash Ratio110.24%

Profitability Ratios

EW profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 26.19% underscores its earnings before tax deductions. The effective tax rate stands at 12.37%, revealing its tax efficiency. The net income per EBT, 87.87%, and the EBT per EBIT, 101.61%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 25.77%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin26.19%
Effective Tax Rate12.37%
Net Income per EBT87.87%
EBT per EBIT101.61%
EBIT per Revenue25.77%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.75, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 700.58% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding232
Days of Inventory Outstanding307
Operating Cycle359.29
Days of Payables Outstanding276
Cash Conversion Cycle83
Receivables Turnover7.01
Payables Turnover1.32
Inventory Turnover1.19
Fixed Asset Turnover3.29
Asset Turnover0.63

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.88, and free cash flow per share, 0.40, depict cash generation on a per-share basis. The cash per share value, 2.82, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.09, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.88
Free Cash Flow per Share0.40
Cash per Share2.82
Operating Cash Flow Sales Ratio0.09
Free Cash Flow to Operating Cash Flow Ratio0.45
Cash Flow Coverage Ratio0.85
Short Term Coverage Ratio21.30
Capital Expenditure Coverage Ratio1.82
Dividend Paid and Capex Coverage Ratio1.82

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 6.39%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.09, we discern the balance between debt and equity financing. The long-term debt to capitalization, 7.74%, and total debt to capitalization, 8.04%, ratios shed light on its capital structure. An interest coverage of 56.96 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio6.39%
Debt Equity Ratio0.09
Long Term Debt to Capitalization7.74%
Total Debt to Capitalization8.04%
Interest Coverage56.96
Cash Flow to Debt Ratio0.85
Company Equity Multiplier1.37

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 9.90, provides a glimpse into top-line earnings distributed across each share. Net income per share, 2.31, reflects the portion of profit attributed to each share. The book value per share, 10.96, represents the net asset value distributed per share, while the tangible book value per share, 8.30, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share9.90
Net Income Per Share2.31
Book Value Per Share10.96
Tangible Book Value Per Share8.30
Shareholders Equity Per Share10.96
Interest Debt Per Share1.17
Capex Per Share-0.44

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 11.56%, indicates top-line expansion, while the gross profit growth, 7.51%, reveals profitability trends. EBIT growth, -12.26%, and operating income growth, -12.26%, offer insights into operational profitability progression. The net income growth, -7.85%, showcases bottom-line expansion, and the EPS growth, -6.10%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth11.56%
Gross Profit Growth7.51%
EBIT Growth-12.26%
Operating Income Growth-12.26%
Net Income Growth-7.85%
EPS Growth-6.10%
EPS Diluted Growth-5.74%
Weighted Average Shares Growth-1.99%
Weighted Average Shares Diluted Growth-2.37%
Operating Cash Flow Growth-99.57%
Free Cash Flow Growth-99.45%
10-Year Revenue Growth per Share224.29%
5-Year Revenue Growth per Share66.85%
3-Year Revenue Growth per Share40.49%
10-Year Operating CF Growth per Share-98.78%
5-Year Operating CF Growth per Share-99.42%
3-Year Operating CF Growth per Share-99.49%
10-Year Net Income Growth per Share295.50%
5-Year Net Income Growth per Share100.87%
3-Year Net Income Growth per Share74.78%
10-Year Dividend per Share Growth per Share-100.00%
5-Year Dividend per Share Growth per Share-100.00%
R&D Expense Growth13.39%
SGA Expenses Growth16.39%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 45,811,775,000, captures the company's total value, considering both debt and equity. Income quality, 0.64, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.30, gauges operational efficiency, while the research and development to revenue, 17.85%, highlights investment in innovation. The ratio of intangibles to total assets, 17.96%, indicates the value of non-physical assets, and capex to operating cash flow, -29.73%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value45,811,775,000
Income Quality0.64
Sales General and Administrative to Revenue0.30
Research and Development to Revenue17.85%
Intangibles to Total Assets17.96%
Capex to Operating Cash Flow-29.73%
Capex to Revenue-4.43%
Capex to Depreciation-183.78%
Stock-Based Compensation to Revenue2.32%
Graham Number23.88
Return on Tangible Assets18.26%
Graham Net Net0.35
Working Capital2,840,300,000
Tangible Asset Value5,037,500,000
Net Current Asset Value1,391,900,000
Average Receivables768,000,000
Average Payables201,650,000
Average Inventory1,021,850,000
Days Sales Outstanding51
Days Payables Outstanding53
Days of Inventory On Hand309
ROIC18.29%
ROE0.21%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 7.39, and the price to book ratio, 7.39, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.57, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 221.25, and price to operating cash flows, 99.57, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio7.39
Price to Book Ratio7.39
Price to Sales Ratio8.57
Price Cash Flow Ratio99.57
Price Earnings to Growth Ratio2.39
Enterprise Value Multiple28.20
Price Fair Value7.39
Price to Operating Cash Flow Ratio99.57
Price to Free Cash Flows Ratio221.25
Price to Tangible Book Ratio6.96
Enterprise Value to Sales7.63
Enterprise Value Over EBITDA23.55
EV to Operating Cash Flow51.14
Earnings Yield3.03%
Free Cash Flow Yield1.36%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Edwards Lifesciences Corporation (EW) on the NYSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 37.199 in 2024.

What is the ticker symbol of Edwards Lifesciences Corporation stock?

The ticker symbol of Edwards Lifesciences Corporation stock is EW.

What is company IPO date?

IPO date of Edwards Lifesciences Corporation is 2000-03-27.

What is company current share price?

Current share price is 87.420 USD.

What is stock market cap today?

The market cap of stock today is 52679292000.000.

What is PEG ratio in 2024?

The current 2.387 is 2.387 in 2024.

What is the number of employees in 2024?

In 2024 the company has 19800.